USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name: RECOMBINANT TECHNOLOGIES, LLC
City: CHESHIRE
State: CT
Zip+4: 06410-7106
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
Website URL: N/A
Phone: N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $898,204.00 4
SBIR Phase II $674,976.00 1

Award List:

Protein Arrays: Phosphorylation-dependent Interactions

Award Year / Program / Phase: 2001 / SBIR / Phase I
Agency: HHS
Principal Investigator: Pazhani Sundaram
Award Amount: $122,437.00
Abstract:
DESCRIPTION (provided by applicant): Protein-protein interactions are central to the process of signal transduction in biological systems. Transmembrane receptor tyrosine kinase (RTKs) play important roles in many aspects of cell growth and behavior. Activated RTKs,… More

Detoxification Depot for Beta-amyloid peptides

Award Year / Program / Phase: 2003 / SBIR / Phase I
Agency: HHS
Principal Investigator: Pazhani Sundaram
Award Amount: $149,800.00
Abstract:
DESCRIPTION (provided by applicant): The long-term goal is to develop an effective therapy for Alzheimer's disease, by using a subcutaneous hydrogel to recognize, concentrate and eliminate beta-amyloid (Abeta) peptides and thereby halt deposition of plaque in the brain. The hydrogel forms in situ… More

Detoxification Depot for b-amyloid peptides

Award Year / Program / Phase: 2005 / SBIR / Phase II
Agency: HHS
Principal Investigator: Pazhani Sundaram
Award Amount: $674,976.00
Abstract:
DESCRIPTION (provided by applicant): The neurotoxic amyloid plaques in the brain, characteristic of Alzheimer's disease (AD), are formed by aggregation of 2 overlapping fragments (AB1-40 and AB1-42) of the amyloid precursor protein. These A-beta peptides can cross the blood-brain barrier. Our… More

ALBUMIN CONJUGATED DETOXIFICATION DEPOT FOR BETA AMYLOID PEPTIDES

Award Year / Program / Phase: 2008 / SBIR / Phase I
Agency: HHS
Principal Investigator:
Award Amount: $351,027.00
Abstract:
DESCRIPTION (provided by applicant): The hallmark of Alzheimer's disease (AD) is the presence in brain of plaques, which are complex extracellular lesions composed of a central deposition of 2-amyloid peptide. Genetic, neuropathological and biochemical evi dence have shown that these deposits play… More

Small molecule therapy for Alzheimer's disease

Award Year / Program / Phase: 2010 / SBIR / Phase I
Agency: HHS
Principal Investigator: Pazhani Sundaram
Award Amount: $274,940.00
Abstract:
DESCRIPTION (provided by applicant): ABSTRACT The objective of our research is to develop an effective therapy for Alzheimer's disease (AD), by using an approach that is able to concentrate, bind and eliminate -amyloid peptides and thereby delay and or halt deposition of plaque in the… More